Canadian Yaz Study
The Food and Drug Administration recently released a study confirming what the British Medical Journal had already suggested in April. The FDA study found that birth control pills containing an ingredient called drospirenone put women at a greater risk of blood clotting than from other types of birth control pills.
The Canadian Medical Association Journal came to the same conclusion, stating that the risk for women taking pills with drospirenone is about 3 or 4 in 1,000. To put it in perspective, the risk from other pills is 1 in 1,000.
If there were only 1,000 women taking these pills, then 3 or 4 blood clotting episodes would be bad enough. But the pills that the BMJ, the CMAJ and the FDA are referring to are Yaz and Yasmin, which are birth control pills made by Bayer. Significantly more than 1,000 women are taking these pills. Hundreds of thousands of women all over the world are taking them, so the threat to the health of these women is much more wide spread.
It should also be mentioned that Bayer engaged in a particularly heavy advertising campaign which made quite a few misleading promises. The advertisements claimed that Yaz could prevent women from gaining weight, could cure acne and could prevent PMS. This wasn’t true. Some people who took the pill did not gain weight, but there isn’t much evidence that suggests that all women would experience the same thing. And some women did experience a clearing up of some pimples. But in the advertisements, they listed symptoms that are commonly associated with PMS, while what Yaz and Yasmin actually had an effect on were symptoms of Pre-Menstrual Dysphoric Disorder. PMDD is significantly different from PMS, and the ads implied that the two conditions were interchangeable.
Continue Reading...